or Try an Advanced Search...

    Technical Analysis for RNAZ - TransCode Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 1.78 8.23% 0.14
    RNAZ closed up 8.23 percent on Friday, May 31, 2024, on 27 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Up Up
    Historical RNAZ trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Inside Day Range Contraction 8.23%
    Wide Bands Range Expansion 8.23%
    Overbought Stochastic Strength 8.23%
    Wide Range Bar Range Expansion 22.41%
    Upper Bollinger Band Walk Strength 22.41%
    Wide Bands Range Expansion 22.41%
    Overbought Stochastic Strength 22.41%
    Gapped Down Weakness 22.41%
    Older End-of-Day Signals for RNAZ ...

       Recent Intraday Alerts

    Alert Time
    Possible NR7 1 day ago
    Rose Above Previous Day's High 1 day ago
    Up 5% 1 day ago
    Up 3% 1 day ago
    Up 2% 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    RNAZ Chart by TradingView
    Basic chart:

    Profile

    TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs for the treatment of metastatic diseases. The company's lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. Its products in discovery and preclinical stage include MicroRNA-10b, TTX-siPDL1, TTX-siLIN28b, and TTX-RIGA, which focuses on treating various cancers. The company was incorporated in 2016 and is based in Boston, Massachusetts
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Preclinical Stage Product Metastatic Cancer

    Is RNAZ a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 29 TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138
    May 13 Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered
    May 13 TransCode Therapeutics Open Letter to Shareholders
    Apr 15 TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors
    Apr 3 TransCode Therapeutics reports FY results
    Apr 3 TransCode Therapeutics Reports 2023 Results; Provides Business Update
    Mar 28 TransCode Therapeutics appoints Vlock as chief medical officer
    Mar 28 TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer
    Mar 11 TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment
    Mar 6 TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress
    See more RNAZ news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 166.4
    52 Week Low 0.42
    Average Volume 1,490,479
    200-Day Moving Average 12.17
    50-Day Moving Average 0.85
    20-Day Moving Average 1.23
    10-Day Moving Average 1.50
    Average True Range 0.27
    RSI (14) 63.77
    ADX 38.51
    +DI 36.79
    -DI 22.34
    Chandelier Exit (Long, 3 ATRs) 1.20
    Chandelier Exit (Short, 3 ATRs) 1.24
    Upper Bollinger Bands 1.97
    Lower Bollinger Band 0.49
    Percent B (%b) 0.87
    BandWidth 120.90
    MACD Line 0.26
    MACD Signal Line 0.20
    MACD Histogram 0.0568
    Fundamentals Value
    Market Cap 1.88 Million
    Num Shares 1.06 Million
    EPS -652.00
    Price-to-Earnings (P/E) Ratio 0.00
    Price-to-Sales 0.00
    Price-to-Book 0.16
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.98
    Resistance 3 (R3) 1.97 1.88 1.95
    Resistance 2 (R2) 1.88 1.83 1.89 1.94
    Resistance 1 (R1) 1.83 1.80 1.86 1.84 1.92
    Pivot Point 1.75 1.75 1.76 1.75 1.75
    Support 1 (S1) 1.69 1.69 1.72 1.71 1.63
    Support 2 (S2) 1.61 1.66 1.62 1.61
    Support 3 (S3) 1.55 1.61 1.60
    Support 4 (S4) 1.57